Monofer (Ferric Derisomaltose)

Ferric derisomaltose, the active ingredient in Monofer, is an iron supplement presented as an injectable solution for intravenous use. It provides elemental iron to replenish depleted stores and supports hemoglobin synthesis, treating iron deficiency anemia in adults and children requiring rapid iron repletion. It is also indicated for patients with chronic kidney disease or those intolerant to oral iron therapy.

GNH USA supplies Monofer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Monofer is used to treat iron deficiency anemia by replenishing iron stores.

Iron deficiency anemia: restores hemoglobin levels and repletes body iron stores. Chronic kidney disease‑related anemia: provides intravenous iron when oral preparations are ineffective or not tolerated. Pre‑operative anemia: raises hemoglobin before surgery to reduce the need for blood transfusion.

Common Side Effects: - Nausea: mild and transient. - Headache: occasional during or after infusion. - Injection site pain: discomfort at the infusion site. - Flushing: brief sensation of warmth or redness. - Dizziness: may occur during infusion. - Mild hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure, potentially leading to shock. - Hypophosphatemia: significant reduction in serum phosphate levels. - Acute respiratory distress: difficulty breathing during or after infusion. - Cardiac arrest: rare but life‑threatening event. - Severe infusion reactions: including chest pain and bronchospasm.

Before initiating therapy, assess iron status and identify underlying causes of deficiency.

Monitor hemoglobin and ferritin levels during treatment to avoid iron overload.

Use caution in patients with known hypersensitivity to iron‑carbohydrate complexes.

Avoid rapid infusion rates; follow recommended administration guidelines.

Observe for signs of hypophosphatemia, especially in patients with renal impairment.

Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Major Interactions (Avoid): - Concurrent IV iron with other parenteral iron preparations: risk of iron overload. - Known hypersensitivity to dextran or other iron complexes: may trigger severe allergic reactions.

Moderate Interactions (Monitor Closely): - Oral phosphate binders: may alter phosphate balance; monitor serum phosphate. - Antacids containing aluminum or magnesium: could affect iron binding; observe for reduced efficacy. - Erythropoiesis‑stimulating agents: may enhance hemoglobin response; adjust monitoring accordingly.